Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors

Giulio Taglialatela, Cristiana Rastellini, Luca Cicalese

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Experimental evidence suggests that the protein phosphatase calcineurin mediates the action of amyloid-β (Aβ) oligomers, the most toxic amyloid species thought to drive initial cognitive decline in Alzheimer's disease (AD). However, there is currently no evidence that inhibition of calcineurin could prevent the onset of AD in humans. Here, we report for the first time that individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population. This result prompts further clinical development of calcineurin inhibition as a viable treatment for AD.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalJournal of Alzheimer's Disease
Volume47
Issue number2
DOIs
StatePublished - Jul 24 2015

Fingerprint

Dementia
Alzheimer Disease
Calcineurin
Transplants
Incidence
Amyloid
Poisons
Phosphoprotein Phosphatases
Graft Rejection
Calcineurin Inhibitors
Population
Inhibition (Psychology)
Therapeutics

Keywords

  • Alzheimer's disease
  • calcineurin
  • dementia
  • FK506
  • solid organ transplant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors. / Taglialatela, Giulio; Rastellini, Cristiana; Cicalese, Luca.

In: Journal of Alzheimer's Disease, Vol. 47, No. 2, 24.07.2015, p. 329-333.

Research output: Contribution to journalArticle

@article{c468d9eb34ec4515b9308055e84f1530,
title = "Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors",
abstract = "Experimental evidence suggests that the protein phosphatase calcineurin mediates the action of amyloid-β (Aβ) oligomers, the most toxic amyloid species thought to drive initial cognitive decline in Alzheimer's disease (AD). However, there is currently no evidence that inhibition of calcineurin could prevent the onset of AD in humans. Here, we report for the first time that individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population. This result prompts further clinical development of calcineurin inhibition as a viable treatment for AD.",
keywords = "Alzheimer's disease, calcineurin, dementia, FK506, solid organ transplant",
author = "Giulio Taglialatela and Cristiana Rastellini and Luca Cicalese",
year = "2015",
month = "7",
day = "24",
doi = "10.3233/JAD-150065",
language = "English (US)",
volume = "47",
pages = "329--333",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Reduced Incidence of Dementia in Solid Organ Transplant Patients Treated with Calcineurin Inhibitors

AU - Taglialatela, Giulio

AU - Rastellini, Cristiana

AU - Cicalese, Luca

PY - 2015/7/24

Y1 - 2015/7/24

N2 - Experimental evidence suggests that the protein phosphatase calcineurin mediates the action of amyloid-β (Aβ) oligomers, the most toxic amyloid species thought to drive initial cognitive decline in Alzheimer's disease (AD). However, there is currently no evidence that inhibition of calcineurin could prevent the onset of AD in humans. Here, we report for the first time that individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population. This result prompts further clinical development of calcineurin inhibition as a viable treatment for AD.

AB - Experimental evidence suggests that the protein phosphatase calcineurin mediates the action of amyloid-β (Aβ) oligomers, the most toxic amyloid species thought to drive initial cognitive decline in Alzheimer's disease (AD). However, there is currently no evidence that inhibition of calcineurin could prevent the onset of AD in humans. Here, we report for the first time that individuals chronically treated with calcineurin inhibitors to prevent solid organ transplant rejection have a significantly lower incidence of AD/dementia as compared to the general population. This result prompts further clinical development of calcineurin inhibition as a viable treatment for AD.

KW - Alzheimer's disease

KW - calcineurin

KW - dementia

KW - FK506

KW - solid organ transplant

UR - http://www.scopus.com/inward/record.url?scp=84938694779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938694779&partnerID=8YFLogxK

U2 - 10.3233/JAD-150065

DO - 10.3233/JAD-150065

M3 - Article

C2 - 26401556

AN - SCOPUS:84938694779

VL - 47

SP - 329

EP - 333

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -